These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10847114)

  • 1. Dofetilide for atrial fibrillation.
    Med Lett Drugs Ther; 2000 May; 42(1078):41-2. PubMed ID: 10847114
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemical cardioversion of atrial fibrillation with intravenous dofetilide.
    Sedgwick ML; Lip G; Rae AP; Cobbe SM
    Int J Cardiol; 1995 Apr; 49(2):159-66. PubMed ID: 7628887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dofetilide for atrial fibrillation.
    Rubin SA
    N Engl J Med; 2000 Jan; 342(4):289-90. PubMed ID: 10660387
    [No Abstract]   [Full Text] [Related]  

  • 4. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.
    Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA
    J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H; Saliba W
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dofetilide (Tikosyn): a new drug to control atrial fibrillation.
    Saliba WI
    Cleve Clin J Med; 2001 Apr; 68(4):353-63. PubMed ID: 11326815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
    Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ
    N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
    Singh SN
    Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.
    Nagra BS; Ledley GS; Kantharia BK
    J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):191-5. PubMed ID: 16211208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dofetilide-induced long QT and torsades de pointes.
    Aktas MK; Shah AH; Akiyama T
    Ann Noninvasive Electrocardiol; 2007 Jul; 12(3):197-202. PubMed ID: 17617063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dofetilide: is the treatment worse than the disease?
    Lauer MR
    J Am Coll Cardiol; 2001 Mar; 37(4):1106-10. PubMed ID: 11263616
    [No Abstract]   [Full Text] [Related]  

  • 12. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH; Decara JM
    Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations for dofetilide use in the elderly.
    Crist LW; Dixon DL
    Consult Pharm; 2014 Apr; 29(4):270-4. PubMed ID: 24704896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dofetilide for the treatment of atrial fibrillation in patients with congestive heart failure.
    Torp-Pedersen C; Moller M; Kober L; Camm AJ
    Eur Heart J; 2000 Aug; 21(15):1204-6. PubMed ID: 10924306
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.
    Suttorp MJ; Polak PE; van 't Hof A; Rasmussen HS; Dunselman PH; Kingma JH
    Am J Cardiol; 1992 Feb; 69(4):417-9. PubMed ID: 1734660
    [No Abstract]   [Full Text] [Related]  

  • 16. Atrial fibrillation in heart failure.
    Stevenson WG; Stevenson LW
    N Engl J Med; 1999 Sep; 341(12):910-1. PubMed ID: 10486424
    [No Abstract]   [Full Text] [Related]  

  • 17. Dofetilide-Induced Severe Hepatotoxicity.
    Subedi R; Dean RK; Dhamoon AS
    Am J Ther; 2018; 25(6):e783-e784. PubMed ID: 29912716
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter.
    Lindeboom JE; Kingma JH; Crijns HJ; Dunselman PH
    Am J Cardiol; 2000 Apr; 85(8):1031-3. PubMed ID: 10760352
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and effectiveness of dofetilide for conversion of atrial fibrillation and nesiritide for acute decompensation of heart failure: a report from the cardiovascular and renal advisory panel of the Food and Drug Administration.
    Grines CL
    Circulation; 2000 May; 101(21):E200-1. PubMed ID: 10831533
    [No Abstract]   [Full Text] [Related]  

  • 20. Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation.
    Torp-Pedersen C; Brendorp B; Køber L
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2695-704. PubMed ID: 11060831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.